Compare Ascendis Pharma A/S (ASND) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Essex Property Trust, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Essex Property Trust, Inc. trades at $293.55 (market cap $18.86B). The key difference: Ascendis Pharma A/S and Essex Property Trust, Inc. are close in size by market cap, and Essex Property Trust, Inc. pays a 3.53% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ESS | |
|---|---|---|
Market Cap | $17.74B | $18.86B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $298.33 |
52-Week Low | $163.32 | $239.61 |
Enterprise Value | $18.11B | $25.59B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ESS trades at $293.55, up 0.83% on the day, with a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 30.03% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and the company's addition to the Russell Microcap Index, reflecting positive momentum.
The outlook for ESS is supported by strong West Coast rental demand and AI-driven employment growth, though risks include high debt levels and Seattle market weakness. Analyst consensus is mixed with a $292.89 price target, slightly below the current price, indicating cautious optimism amid valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
